New data from Brii Bio's Phase 2 ENSURE study reveals that patients who responded to BRII-179 achieved a 55.6% HBsAg seroclearance rate, compared to just 10% in non-responders, supporting a novel patient enrichment strategy.
Brii Bio has acquired full intellectual property rights to BRII-179 from VBI Vaccines for $18 million, securing uninterrupted clinical supply and complete ownership.
A Phase 2 trial of tobevibart and elebsiran, with or without pegylated interferon alfa, shows promising HBsAg loss rates in chronic hepatitis B patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.